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Food contamination by Deoxynivalenol: an environmental risk factor for Crohn’s disease?





Crohn’s disease is one of the most common inflammatory bowel diseases empirically defined by microscopic analysis of intestinal biopsies. In contrast to other inflammatory bowel diseases, Crohn’s disease is generally characterized by inflammatory lesions in the form of sinuses, fistulae, and fissures, which are segmented and patched, and dispersed mainly to the upper gastrointestinal tract (Odze 2003). Furthermore, the presence of transmural non-caseating granuloma’s is a distinguishable feature of Crohn’s disease (Xavier 2007). A great deal of work has focused on the underlying mechanisms responsible for the induction or propagation of the symptoms of CD. Although no factor has been pinpointed to be exclusively responsible for the pathogenesis of CD, it has become clear that both environmental and genetic factors may contribute to this disease, as shown by epidemiologic, genetic, and environmental studies. 
The incidence of Crohn’s disease differs between geographic region and racial background. In Europe, incidences increase along a south to north gradient, with incidences of 7/105 in northern countries and 3.9/105 in countries below the Alps. Incidences in the USA, Canada, and Australia are comparable to North Europe.  In South America and Eastern Asia incidences are lower than 1 per 105, whilst Saudi-Arabia and South Africa have incidences that range between 1-4/105(Economou 2009). 
Although the incidences of Crohn’s disease differ markedly worldwide, they have been increasing the last couple of decades in almost all areas investigated. Such a sudden increase in cases suggests that environmental factors are likely to play a role in the pathogenesis of Crohn’s disease. 
Besides differences between geographic regions, racial background and family occurrence also influences the susceptibility to Crohn’s disease. For example, in Israel, Jews from American or European descent have a higher risk to develop Crohn’s disease than individuals from Asian or African descent (Niv 1999). Furthermore, twin studies show that the concordance rate of CD in monozygotic twins is between 20-50% whereas dizygotic twins have a concordance between 0 and 7% (Halme 2006). Other studies on familial occurrence reveal that the chance of CD in offspring is around 33% when both parents are affected (Laharie 2001). This suggests that besides environmental factors, genetic factors contribute to the pathogenesis. 
Numerous studies have tried to correlate specific environmental and genetic factors to Crohn’s disease. One of the most thoroughly studied genetic factors linked to CD is the presence of uncommon polymorphisms in the nod 2 gene (Watts 2002), which encodes for an intracellular receptor that activates NF-kB upon recognition of bacterial peptidoglycans and LPS by its leucine rich repeat domains (LRR; Inohara 2001). Three of the most common polymorphisms observed in NOD2 associated with CD tampers with the ability of the LRR to recognize bacterial products and results in a diminished NF-kB production (Bonen 2003). Carriers of polymorphisms in this gene have a relative risk to develop Crohn’s disease up to 44 (Watt 2002). Other polymorphisms implicated in increased susceptibility to CD include mutations in the Th-1 polarizing cytokine TNFSF15 [in Japanese and UK cohorts], a polymorphism in ATG16L1, a protein implicated in bacterial processing in autophagosomes, and polymorphisms causing altered expression of the prostaglandin receptor gene PTGER4. Furthermore, a mutation in IL-23R is associated with a decreased susceptibility and immune suppression (Cho 2008). [Genetic factors: table] 
An interplay between genetic and environmental factors in the pathogenesis of CD have been stressed by numerous studies, as the lack of common genetic susceptibility factors in some patients (Joossens 2007), the presence of these genetic factors in non-affected people (Vind 2005), the worldwide increase in cases the last 2 decades, and the lack of full concordance between monozygotic twins point towards the involvement of non-genetic factors. Of all environmental factors, appendectomy, tobacco smoking, and oral anti conceptive use have been most intensively studied in it association with CD. A meta-analysis of studies on the association of CD with appendectomy (the removal of the appendix) showed an increased relative risk to develop CD in the first years after appendectomy, although it is not clear whether this correlation is a result of misdiagnosed CD (as abdominal pain can result from both CD and appendicitis), or if appendectomy is able to evoke CD (Kaplan 2008). Exposure to tobacco smoking has also been shown to contribute significantly to the risk of getting CD. Both active smoking during childhood, passive smoking by exposure from others and prenatal tobacco exposure by maternal smoking is increased in CD patients in a case-control study (Mahid 2007). Furthermore, cessation of smoking significantly alleviates the symptoms of CD (Lakatos 2007). A meta-analysis of several studies reporting on oral contraceptive use and Crohn’s disease showed a slight increase in risk when combining the study results, although non-causative explanations for this effect cannot be excluded and some show a negative correlation (Godet 1995). Many other environmental factors have been proposed to instigate or initiate Crohn’s disease including: infectious agents such as measles (Thompson 1995) or mycobacteria avium paratuberculosis (Hermon-Taylor 2001), childhood exposure to refrigerators/freezers (Malekzadeh 2009), psychosomatic stress, absence of helminthes infections (Elliot 2000), intake of microparticles from toothpaste (Sullivan 1990), consumption of animal food products (Asakura 2008), and the composition of the intestinal microflora (Mylonaki 2005). However, a correlation for many of these factors have been contradicted by subsequent research, such as for measles (Davis 2001), for some factors elimination or decrease of exposure have not resulted in alleviation of the disease, as for microparticles (Lomer 2005) and mycobacterium avium paratuberculosis (Selby 2007), and some factors lack direct causative evidence (such as for the composition of intestinal microflora (Gophna 2006)).   
 
DON
The fungus Fusarium is the pathogenic agent of the plant disease fusarium head blight or scab and infects various economically important cereal crops worldwide, including wheat, maize, rice and barley. The most frequent and pathogenic fusarium subspecies include fusarium graminearum, which is predominantly found in warm and humid climates, and fusarium culmorum, which mainly infects crops in cooler climates.  Fusarium head blight not only results in reduced quality and size of the harvest, but also causes contamination with various mycotoxins, especially the trichothecene deoxynivalenol (DON) (Osborne 2007).  DON is produced by various Fusarium subspecies and is involved in fungal spread in infected cereals (Bai 2001). The presence of DON in primary harvest may result in contamination of cereal-based food and feed products, as DON is not eliminated by various food processes, including milling and cooking (Kushiro 2008).
In animals, exposure to DON from naturally contaminated feed and experimental administration causes symptoms like vomiting, reduced food intake and weight loss, altered immune function, embryonic mortality and reduced productivity in farm animals and pets, including chicken (Yegani 2006), swine (Tiemann 2007), cows (Korosteleva 2009), and cats and dogs (Hughes 1999). Food emises is a particular symptom in cats, dogs, and swine after acute high dose exposure to DON, hence the trivial name vomitoxin (Tiemann 2007; Hughes 1999). The sensitivity to DON differs per animal, with swine being the most, and cows being the least sensitive (Pestka 2005b). Based on the effects in animals, risk assessment studies were conducted by the Scientific Committee of Food of the European Union and the joint FHO/WHO Expert Committee on Food Additives to provide a tolerable daily intake (TDI) of DON in humans of 1ug/kg bw (Canady 2001; SCF 2002).
The 2003 mycotoxin analysis of food products in the European Union showed that 57% of the food products tested contained DON, with wheat and bread the largest contributors to DON exposure (Schothorst 2004). This study also showed that particularly children are at high risk to exceed the TDI for DON.  Another study, by Turner et al (2008), in the UK showed a direct correlation between the amount of cereal intake and the concentration of DON in urine samples, and 98.7% of cereal-consumers excreted DON in the urine. Notably, it is estimated that about 5% of the UK adults exceed the TDI for DON (Turner 2008).   
In human, exposure of the intestinal tract to DON is of particular significance, due to the inability of intestinal bacteria to convert DON in de-epoxydated DON, a less toxic metabolite (Eriksen 2003; Eriksen 2004). Acute exposure to high concentrations of deoxynivalenol has been correlated to food poisoning outbreaks in China and India (Bhat 1989; Li 1999), causing abdominal pain, diarrhea and other gastrointestinal symptoms after consumption of contaminated bread (Bhat 1989). The effect of long term in vivo exposure to DON in humans is not well understood. 

DON metabolism
The pharmacokinetic properties of toxins, defined by absorption, distribution, metabolism, and elimination, play a critical role in the overall toxicity of the compound. This is especially important for DON, due to the concentration-dependent ambiguous effect it can have in biological processes. Furthermore, the animal models tested show a great variation in sensitivity to DON, and is likely to be influenced by the pharmacokinetic fate of DON.   
Absorption of DON by the gastrointestinal tract differs greatly among animal species, and may especially account for observed differences in sensitivity to DON in these animals. Systemic absorption of orally administered DON is the highest in swine, reaching 60% after exposure of 5.7mg/kg for 4 weeks (Goyarts 2006).The bioavailability in other animals, such as ruminants and chicken is dramatically lower, with absorption of 7.5% in sheep (single oral dose of 5mg/kg)(Prelusky 1985), and even less than 1% in cows and chicken after a single oral dose of 920mg (Prelusky 1984) and 2.2mg 14C-DON, respectively (Prelusky 1986). The wide range of absorption between these animals results partly from differences in the potential of gastrointestinal microorganisms in these animals to convert DON in less toxic metabolites. For example, the microbial content of the hindgut of chicken has been shown to convert 99% of DON into the non-toxic metabolite de-epoxy DON (DOM-1) (He 1992), and microorganisms isolated from the rumen of cows show similar properties, albeit to a lesser extent (Swanson 1987; He 1992). 
The high absorption levels of DON in swine may be correlated to the inability of its microbial content to convert DON into DOM-1, although results are somewhat controversial between studies.  He et al showed that microorganisms isolated from the large intestine of swine were not capable to decrease the DON concentration or transform it into DOM-1 (He 1992). Furthermore, Prelusky et al (1991) did not observe extensive metabolism of DON in the feces of exposed swine. On the other hand, de-epoxidated DON was found in feces of swine exposed to 3-acetyl DON (Eriksen 2003), and microorganisms of the caudal part of the swine intestine were able to form DOM-1 (Kollarczik 1994). However, the inability of microorganisms in the upper part of the intestinal tract to convert DON, where almost all absorption of DON takes place (Danicke 2004), and the low amounts of DOM-1 found in the feces and complete absence in the blood and urine of exposed swine suggests that de-epoxydating bacteria in these animals do not influence the extensive absorption of the parental compound.
After chronic oral administration of DON to swine (5.7mg/kg for 4 weeks and subsequently one similar dosage after a 17h feed withdrawal), absorption of DON followed rapidly, with measurable serum concentrations already after 5 to 15 minutes, and maximum serum concentrations of 17 to 25ng/ml were reached after 45min tot 2h (Goyarts 2006). The mean volume of distribution in chronically exposed pigs in these experiments was 2.65 l/kg, thus exceeding the total volume of body water. As DON does not readily bind to plasma proteins, it is likely that distribution to tissues takes place (Goyarts 2006; Prelusky 1988). The distribution of DON in various tissues has been measured in pigs after intravenous administration (1mg/kg) (Prelusky 1991). This data showed that DON has high initial concentrations in plasma, kidney and liver, followed by abdominal- and back fat, lymph, lung, adrenals, spleen, and testis. Low concentrations were found in brain, heart, muscle, skin, intestine and pancreas. After 24h, trace levels of DON were only observed in tissues with high initial concentrations (Prelusky 1991). A similar distribution pattern has been observed in mice after oral DON exposure. In animals fed a single oral dose of 25mg/kg DON, levels were highest in liver, kidney, spleen, and heart. Low levels were also observed in the brain of mice (Pestka 2008).       
It is interesting to note that the distribution of DON to specific areas in the brain might be responsible for the effects of DON on feed intake and the induction of emesis in pigs. In rats, it has been shown that the area postrema is responsible for the reduced feed intake (Ossenkopp 1994), and other studies reported differences in neurotransmitter concentrations in the brain of exposed swine (Prelusky 1992; Prelusky 1993). Furthermore, certain specific serotonin receptor antagonists were able to block DON induced vomiting in swine, as well as intravenous administration of chlorpromazine, which acts on the chemoreceptor trigger zone in the central nervous system involved in induced vomiting (Prelusky and Trenholm 1993).   
After absorption, DON may be metabolized by phase II enzymes into less toxic products, including glucuronide conjugated DON (Wu 2007). In swine, the ability to convert DON into glucuronide conjugated DON differs among studies. Some detected only trace concentrations of conjugated DON in feces, serum, or urine (Prelusky 1988), while others observed significant proportions of glucuronide-conjugated DON in plasma (42%) or urine (33%) (Eriksen 2003). Also, differences were observed between different routes of administration and between acute and chronic exposure to DON. In pigs intravenously exposed to 53mg/kg bw DON, serum was free of conjugated DON, except in two cases with low amounts (5-7%) of conjugated DON. On the other hand, both acute and chronically exposed pigs had higher concentrations of conjugated DON in the serum, ranging from 15-36% after chronic exposure, and 9.1-60% after acute exposure (Goyarts 2006). In human, both DON and glucuronide conjugated DON have been observed in urine from people in an area with high endemic exposure to DON from cereals (Meky 2003).   
The elimination half-life of DON from the serum of pigs has been described in several reports. Goyarts et al (2006) observed an average half time of 6.3h and 5.3h after chronic and acute exposure, whereas intravenous administration resulted in a much slower half-life of 15h. The slower half-life after intravenous exposure might be due to a lack of the hepatic first-pass clearance of DON (Goyarts 2006). Another study observed a faster half-life of 6.5h after intravenous administration of radioactively labeled DON (300ug/kg bw) in pigs, and this was comparable to the elimination after intragastric administration of 600ug/kg bw (7.1h) (Prelusky 1988). Mice show a slightly higher clearance half-live of 11.8h after oral administration of 25mg/kg bw (Pestka 2008). On the other hand, clearance of DON from the plasma of sheep occurs much faster, with elimination half-times of 57-78min and 100-125min after intravenous and oral administration of DON, respectively (Prelusky 1985).  
In the study by Goyarts et al, the total recovery was 54% of the total DON intake in the chronically fed group. About 50% of the total intake of DON was found in the urine, whereas only 2.5% was recovered in the feces (Goyarts 2006). Recovery percentages were much higher in a study by Prelusky, which observed a recovery of DON was 68% in urine, 1-3% in bile, and 20% in the feces after intragastric administration (Prelusky 1988) Following intravenous administration, approximately 95% was recovered in urine, whereas 5% was collected in bile in a 24h time period. Others also showed that the majority of DON (dosage 2.5mg/kg feed) was excreted in the urine, and only a small percentage was excreted through the feces (Ericksen 2003) 
A number of studies observed traces of DON in urine and/or feces after 24 to 48h after exposure, while plasma concentrations were below the detection limit. This supports a role for deep compartment tissues, such as fat, in the release of DON during this slow elimination phase (Prelusky 1988; Eriksen 2003).
Although the fate of DON in a human setting is not clear, it is likely that the toxicokinetics in human are comparable to that in swine. For instance, bacteria from human feces are not able to convert 3-acyl DON into DOM-1, but can acetylate 3-acyl DON into DON (Eriksen and Petterson (2003), and it is thus likely that the majority of ingested DON will reach some part of the gastrointestinal tract as parental compound. 

Besides encountering pathogens, the intestinal epithelium is also exposed to orally ingested xenobiotic toxins. The lipid membrane of epithelial cells provides an impermeable barrier against water-soluble toxins. However, many xenobiotics are lipophilic and can penetrate the cell by simple diffusion, including dietary carcinogens like PHiP, which is formed during frying or cooking of meat, mycotoxins, and pesticides (Leslie 2004). In order to eliminate these lipophilic xenobiotics, the intestinal epithelium expresses drug-metabolizing enzymes (DME) that convert them into more hydrophilic compounds. This also renders most xenobiotics less toxic metabolites, although some xenobiotic compounds have increased toxicity after metabolism, such as aflatoxin B1. Increased hydrophilic compounds are also better available for secretion into the intestinal lumen by transmembrane drug transporters (Xu 2004). Based on their function, DMEs are diverted into phase I, II, and III enzymes. 
Phase I enzymes consist of a large group of enzymes in human, called cytochromes P450 (CYP), and function in the oxidation, peroxidation and reduction of lipophilic endogenous substances and xenobiotics. At least four of these gene families, CYP1-4, metabolize xenobiotics including bacterial and fungal derived secondary products, environmental and chemical pollutants, and prescription drugs (Nebert 2002). CYP3A, one of the major families of CYPs abundantly expressed in the intestinal tract and liver, has been correlated to the metabolism of over 50% of all prescription drugs (Kliewer 2003). Furthermore, it plays an important role in the metabolic conversion of the mycotoxins including aflatoxin B1(Kolars 1994), zeralenone (Ding 2006) and ochratoxin A (Zepnik 2001), although for the latter mycotoxin results are conflicting (Simarro Dorten 2003). Regarding phase I enzymes, the faith of DON is less clear. Unlike aflatoxin B1, it does not seem to be metabolized into more cytotoxic compounds by the major xenobiotic metabolizing CYPs (Lewis 1999). Furthermore, earlier studies showed that the levels of microsomal CYP450 in the liver were not altered in DON-fed rats (20ppm for 90 days) (Morrissey 1985). On the other hand, the expression of the CYP2B subfamily is upregulated in liver microsomes of DON-fed mice (0.071 mg/kg bw for 4 weeks), whereas CYP1A expression was not altered (Gouze 2005).  
Reactions mediated by phase I enzymes generate a hydroxyl group that allows the attachment of functional groups by phase II molecules (Handschin 2003). Several different enzymes are responsible for phase II reactions of paternal xenobiotics and metabolites produced by phase I proteins. A number of phase II enzyme play a pivotal role in the detoxification of xenobiotics in the intestinal tract, mainly by attaching hydrophilic groups to phase I metabolites or their parental compounds with reactive groups. Important phase II enzymes include: UDP-glucuronyl transferase (UGT), which catalyzes the attachment of the hydrophilic UDP-glucuronic acid (Tukey 2000); glutathione-S-transferase (GST), which is involved in the transfer of the tripeptide glutathione (Kaminsky 2003); and cytosolic sulfotransferase, which transfers a sulfonyl group (SO3-) from 3’ phosphoadenosine 5’phosphosulfate to xenobiotic acceptor (Gamage 2006). 
The expression of cytosolic GST in livers of mice is enhanced after oral feeding of DON (0.071 mg/kg bw for 4 weeks), and it is likely that DON serves as a substrate for this enzyme as it competitively inhibits binding of another substrate (Gouze 2005). The involvement of other phase II enzymes in the metabolism of DON in human and animal species is not clear. In plants, the UGT protein DOGT1 expressed by Arabidopsis thalinia has shown to catalyze the transfer of UDP to DON and this produces a less toxic metabolite (Poppenberger 2003). For other mycotoxins, like the trichothecenes T-2 toxin, UGT levels are increased in rats exposed this mycotoxin (Kravchenko 1986). In contrast, UDP transferase activities and levels were not altered in T-2 exposed pigs (Meissonnier 2008) and rabbits (Guerre 2000).  
Once xenobiotic compounds have turned into more hydrophilic metabolites, they can be eliminated by the phase III DMEs, which are the ATP-binding cassette (ABC) transporters (Leslie 2004). These proteins mediate the energy-dependent (i.e. ATP consuming) transport over the cellular membrane, thereby decreasing the intracellular concentration of the xenobiotics or their metabolites. In human, 7 subfamilies of ABC transporters are known, and many of them have been discovered in the search for multi-drug resistant proteins (MDR) in cancers, as the ABC transporters are also associated with the removal of anti cancer agents from the intracellular milieu. Three of them, ABCB1/MDR1/P-glycoprotein, ABCC2/MDR-associated protein-2 (MRP-2), and ABCG2/breast cancer resistant protein, have been detected at mRNA and protein levels in the small intestine (Nakamura 2008), and are potentially involved in the excretion of xenobiotics into the lumen of the intestinal tract. 
ABC transporters mediate the removal of several mycotoxins from the cell, including ochratoxin A by MRP2 (Berger 2003), and aflatoxin B1 by BCRP (van Herwaarden 2006). For DON the involvement of ABC transporters was suggested as ATPase inhibitors significantly diminished the basolateral to apical transport in human Caco-2 cells. Overexpression of two of these ABC transporters, Permeability glycoprotein (P-gp), and MRP2, resulted in a decreased accumulation of DON in the cytoplasm, and this effect could be reversed by specific transport inhibitors. (Videmann 2007) 
The expression of the DMEs is controlled and coordinated by several ligand-activated nuclear receptors. These factors are composed of a DNA-binding domain, which mediates binding to a promoter element of one or several target genes, and a ligand-binding domain allows specific activation by one or more ligands. A wide range of ligands have been recognized to induce activation of these nuclear receptors and include endogenous derived steroid hormones, thyroid hormones, hydrophilic vitamins, bile acids, fatty acids, and xenobiotics (Nakata 2006). The nuclear receptors that are able to interact with and respond to intracellular xenobiotic compounds include the aryl hydrocarbon receptor (AhR), which is expressed in most tissues and cells lines, and the constitutive androstane receptor (CAR) and pregnane X receptor, which are almost exclusively expressed in the liver and intestine (Pascussi 2004). Besides these widely recognized xenobiotic activated nuclear receptors (also called xenosensors), peroxisome proliferators-activator receptor (PPAR), which sense endogenous derived fatty acids as their natural ligands, can also be activated after xenobiotic exposure (Kliewer 1999). Other nuclear factors like the farnsesol X receptor cannot bind xenobiotics directly, but potentially influences xenobiotic sensing indirectly by regulating the expression of xenosensors, e.g. farnesoid X receptor is able to induce the expression of PXR upon binding with bile acids (Jung 2006). Furthermore, many nuclear factors with different ligands have overlapping target genes, as with the vitamin D receptor (VDR), which is also able to induce transcription of PXR and CAR target genes. It is thus conceivable that e.g. vitamin D stimulated induction of VDR results in an increased expression of DMEs involved in the clearance of xenobiotics (Drocourt 2002). 
Of all the nuclear receptors, PXR is of particular importance, as it is highly expressed in both liver and intestine, recognizes a diverse spectrum of ligands, and serves as a master regulator of the expression of CYP3A, the key enzyme in phase I xenobiotic metabolism in the intestine and liver (Kliewer 2003). 
PXR also regulates a number of phase II DMEs, such as UGT, GST, and sulfotransferases, and phase III transporters P-gp, BCRP, and MRP-2 (Kliewer 2003; Kliewer 2005). The role of PXR in the recognition of mycotoxins has only been described for zeralenone, and binding of this ligand results in the increase of CYP3A expression (Ding 2006).
[DON metabolism in the intestinal tract: DOM-1]

Elevated levels of IgA
One of the major functions of the gut is to protect the internal milieu against bacteria in the intestinal lumen, as exposure to intestinal content can provoke unwanted immune responses, and even cause toxic syndromes like endotoxemia. One of the mechanisms to prevent bacterial invasion and excessive immune activation is the production of the dimeric secretory IgA by plasma B cells in the gut. IgA forms the immunodominant antibody isotype in the intestinal lumen, where it coats commensals and pathogenic bacteria to reduce their invasion and colonization (Fagarasan 2006). Furthermore, IgA aids in the removal of intracellular pathogens like viruses and neutralizes intraepithelial immunogenic bacterial products such as lipopolysaccharide (LPS) produced by gram negative bacteria (Schwartz-Cornil 2002; Fernandez 2003). Although IgA forms usually a minor fraction of the antibody isotypes in serum, elevated levels of IgA have been seen in a number of diseases, including human IgA nephropathy, Heinbach-Schonlein purpura, and HIV-infection, and circulating IgA was suggested to originate from mucosal sites (Zhang 2008; Moja 1998; Quesnel 1994).  Also, elevated levels of IgA, and to a lesser extent IgG, specific for the yeasts C albicans and S cerevisiae have been found in serum of patients with Crohn’s disease (Savage 2004). 
Serum IgA levels are also increased upon DON exposure in some experimental animals. In vivo studies show that mice seem to be most sensitive to this effect. Serum IgA levels of high-dose DON-fed (25ppm) mice increase more than 17-fold after 24 weeks of exposure19, and levels remain elevated for up to 16 weeks after 8 weeks of 25ppm exposure5. The reported effect in mice seems to be specific for IgA, as no concomitant increase in levels of other antibody subclasses was observed, but these levels remained unaffected or even diminished 16-18. 
The DON induced IgA serum elevations in mice lead to the formation of IgA immune complexes, which form deposits in the mesangium of the kidney, and results in hematuria and proteinuria. This form of nephropathy in mice closely mimics human IgA nephropathy, and is the leading cause of human glomerulitis. (Dong 1993)   
The effect of serum IgA levels in DON-fed pigs is less uniform between studies. Several studies observed a specific increase in serum IgA in DON-fed pigs after 16.6mg/kg exposure for 11 weeks6,7or 0.6mg/kg for 8 weeks (Pinton 2009). A concomitant increase of serum IgA and IgM and unaffected IgG concentrations was reported by another study (4.6mg/kg for 21 days).23 Others could not reveal any correlation between DON intake and serum antibody concentrations (5.8mg/kg for 3 weeks)24, or observed an increase in IgG and IgM, but not IgA serum concentrations only after acute exposure (single dose of 5.7mg/kg feed), whereas chronic exposure (5 weeks of 5.7mg/kg feed) did not reveal any difference in serum Ig concentrations.8 
DON exposure did not result in an increase in serum antibody concentrations (IgA, IgM, and IgG) in horses (14.1mg/kg for 3 weeks)21 and chicken (9.3-9.7mg/kg for 7 weeks)22, and even decreased IgA levels in cows (3.6mg/kg for 36 days)12. 
A correlation between increased serum IgA levels and DON exposure in humans is not well established. Only one in vitro study showed that supernatant of purified lymphocytes exposed to low concentrations of DON (1.0x10-7M for 7 days) resulted in a slight increase in IgA concentration, IgM and IgG remained unaffected. Higher concentrations (1x10-6M for 7 days) decreased the concentrations of all three antibody subtypes tested.25 

The way DON induces elevated IgA responses in mice is well established, and might provide potential mechanisms in humans for DON induced immune alterations. Under normal conditions, the main inductive site in both mouse and human of intestinal IgA production is the Peyer’s Patch (PP), a part of the gut associated lymphoid tissue (GALT).3 The PP facilitates an environment of cytokines and cell-cell interactions that stimulate the development of precursor B cells into IgA producing plasma cells. Cytokines derived from T cells and macrophages in the PP are critical in this development, and include tumor growth factor (TGF) beta and the interleukins (IL) IL-2, IL-4, IL-5, IL-6, and IL-10.2[ref for IL-2]. Single dose oral exposure of mice to DON (5mg/kg bw[25ppm])  increased mRNA for a number of cytokines in different organs and tissues, including IL-6, IL-10, IL-2 and IL-4 in the PP and spleen, and thus creates an environment to promote the development of IgA producing plasma cells.32,33 Indeed, isolated PP, and to a lesser extent spleen lymphocytes, of DON-fed mice (25ppm for 12 weeks) had higher levels of IgA and IgA-secreting cell numbers compared to control cultures, whereas increase IgG levels were less pronounced. (Pestka 1990b) 10 The importance of T cells in this effect is illustrated by a study showing that combining B cells from PP of control-fed mice with T-cells from PP of DON-fed mice (25ppm for 8 weeks)) is still able to significantly raise IgA supernatant levels, whereas isolated B cells from both spleen and PP of DON-fed mice decreased IgA production upon stimulation with LPS or conA.1,28 Furthermore, the percentage of (CD4+) Th cells and ratio CD4+/CD8+ is higher in PP and spleen of DON-fed mice (25ppm for 12 weeks) when compared to controls, favoring a Th cell mediated differentiation of B cells into plasma cells. (Pestka 1990a)11 DON-induced B-cell differentiation due to T-cell stimulation is likely to be mediated by cytokines, as IL-4, IL-5 and IL-6 are all increased in macrophage-depleted CD4 cells prestimulated with conA and subsequently exposed to DON (25-200 ng/ml) (Warner 1994)18. 
The importance of macrophages in DON-induced IgA production was evaluated by Yan et al. They observed that macrophage depletion of PP of both control fed and DON-fed mice (acute dose of 25mg/kg) resulted in a concomitant decrease in IgA and IL-6 concentration in supernatant. Also, coculturing of B cells and macrophages increased IgA and IL-6 secretion even more than T cells, and this effect was strongly enhanced by the addition of LPS to the cell cultures (Yan 1998).31 
The ability of IL-6 to stimulate IgA production after DON stimulation is underlined by experiments with IL-6 knock-out mice, which are resistant to IgA serum alterations upon DON exposure (25ppm for 12 weeks).20 Furthermore, the upregulation of mitogen stimulated PP and spleen cell cultures from DON-fed mice (25mg/kg; acute dose) can be abolished by neutralizing antibodies to IL-5, IL-6, and to a lesser extent IL-2.29  However, IL6 and other soluble factors are not solely responsible for increased IgA-production, as experiments with permeable membranes showed that cell-cell contact between macrophages and PP cells is necessary to get maximum IgA production.30 
The pathways involved in DON-induced IL-6 production are investigated in vitro in RAW 264.7 macrophages and in vivo in mice. In RAW 264.7 macrophages, DON superinduction (250ng/ml) of IL-6 production in LPS stimulated cells could be inhibited by the COX-2 inhibitors indomethacin and NS398 (Moon 2002). In vivo, COX-2 mRNA is increased in both PP and spleen of DON exposed mice (25mg/kg; acute exposure), and the upregulation preceded or was concomitant with mRNA of IL-6. In addition, DON-fed mice had lower IL-6 mRNA and serum IL-6 levels when pretreated with COX-2 inhibitors. Similarly, COX-2 KO mice were less sensitive to DON-induced splenic IL-6 mRNA upregulation. However, inhibition of COX-2 could not completely abolish the DON-induced upregulation of IL-6 in vivo and in vitro, suggesting that other mechanisms are also involved. (Moon 2003) Surprisingly, IgA serum levels of DON-fed (10mg/kg for 16 weeks) COX-2 KO mice were not significantly decreased when compared to DON-fed (10mg/kg for 16 weeks) WT mice and were significantly higher than control fed WT-mice. Also, COX-2 inhibition by Rofecoxib did not reduce but rather promoted serum IgA levels in DON-fed mice(25mg/kg for 16 weeks)10. 

There are several clues that point towards a similar pathway being activated during DON exposure and in patients with Crohn’s disease. Most notably, IL-6 serum concentrations are higher in subjects with active Crohn’s disease, when compared to negative control subjects or subjects with other gastrointestinal inflammatory disorders, including ulcerative colitis.9,15 Furthermore, elevated serum levels of IL-6 in patients in clinical remission are correlated with an increase in the amount of annual relapses.27 The importance of IL-6 in Crohn’s disease is underlined by a clinical trial with anti-IL-6 neutralizing antibodies that are significantly able to reduce disease activity.4
The source of IL-6 in these patients is suggested to be macrophages and epithelial cells of the colon, as shown by northern blot analysis of isolated colon samples.13 
A correlation between increased IL-6 serum levels and increased IgA serum levels is not well established in Crohn’s disease patients, although, interestingly, 9 IBD cases have been reported with IgA nephropathy (Shaer 2003).
In addition to the induction of IL-6 in both DON exposure and Crohn’s disease, ameliorating effects of fish oil have been proven in both inflammatory models. Feed complemented with fish oil enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) significantly decreases or even abolishes serum IgA elevation, serum IL-6 and IL-6 mRNA in spleen and PP in mice fed with DON (IgA experiments: 10mg/kg for 18 weeks; for IL-6 experiments: acute exposure of 25mg/kg)11. Similarly, consumption of fish oil containing DHA and EPA by Crohn’s disease patients resulted in a decrease or stabilization in inflammatory mediators produced by PBMCs, including IL-6, IFN-gamma, and PGE226. Interestingly, the latter is produced by COX-2, and it is suggested that the decrease of PGE2 is a result of competitive binding of EPA and DHA for arachidonix acid (AA), the precursor of PGE214. Thus both inhibition of COX-2 (in DON model) and substrate competition for COX-2 enzymatic activity (in Crohn’s disease model) decrease the production of proinflammatory cytokines. 

Effect of DON exposure on epithelial cell function
DON-exposure acts on intestinal epithelial cells directly by influencing cytokine production, and barrier function. These studies have mainly been conducted on human carcinoma Caco-2 cells, a cell model widely used to investigate intestinal epithelial functions (Sambuy 2005). In vitro IL-8 production of Caco-2 cells increases ten-fold after the addition of DON at concentrations of 2.5microM or higher. DON-induced upregulation (10microM) of IL-8 is dependent on p38 MAPK, PKR, and NF-kB as the respective protein inhibitors SB203580, adenine, and PDTC significantly abolish this effect. Furthermore, low levels of DON contributed significantly to IL-1beta and LPS induced IL-8 secretion and NF-kB activation in Caco-2 cells, suggesting that DON may exacerbate already existing inflammation (Maresca 2008; Van der Walle 2008)  
DON exposure also has an effect on the epithelial barrier function of Caco-2 cells. Transepithelial electrical resistance (TEER) reductions were seen after Caco-2 cell exposure to DON, at concentrations of 100microM (Maresca 2008), or 0.5micog/ml (Sergent 2006). The latter study showed that the TEER reduction was not a result of barrier disruption through cell death. In the study of Maresca (2008), an increase in the translocation of FITC-dextran and horse radish peroxidase was observed at similar concentrations (100microM).  Interestingly, although exposure of Caco-2 cells to lower concentrations of DON (10microM) did not result in influx of small molecules or a drop of TEER, bacterial translocation of non-invasive commensal E. coli was still observed (Maresca 2008). The mechanism behind the DON-induced TEER reduction has been studied by Pinton (2009) in Caco-2 cells and porcine IPEC-1 cells. In line with other studies, DON induced a dose and time dependent TEER reduction in the Caco-2 cell line, and IPEC-1 was even more sensitive to TEER reduction. The effect on the TEER is not associated with increased cell death at lower concentrations of DON (up to 100 microM in Caco-2 cells and 50microM in IPEC-1 cells). The reduction in TEER was also associated with an increase in translocation of FITC-dextran in both cell lines and bacterial translocation in IPEC-1 cells. Ex vivo porcine intestinal transplants were also more permeable for the paracellular tracer FITC-dextran at 20uM and 50uM of DON (Pinton 2009). 
The increased translocation of bacteria and small molecules can result from both increased transcellular and paracellular permeability. A critical component in the regulation of the paracellular integrity is the tight junction complex between the membranes of adjacent epithelial cells. This allows a regulated semi-permeable seal that segregates the apical and basolateral parts of the cells.  The tight junction complex comprises a number of proteins, including the cytosolic zona occludens (ZO) proteins, and the membrane spanning occludin, junctional adhesion molecules, and claudins (Hossain 2008). Claudins constitute the major part of the tight junction and seem to be of particular importance in the formation of a tight junction strand whereby two opposing membranes are brought together by oligomerization of claudin proteins. Furtermore, a number of claudins have a pore forming ability and are involved in the selective passage of mono- and divalent cations (Krause 2008). 
The increased permeability in DON treated epithelial layers can at least in part be contributed to a diminished expression of tight junction molecules. Claudin-4 expression was lower in DON-treated (30uM for 48h) Caco-2 cells and claudin-3 and 4 in IPEC-1 cells, as measured by immunohistochemistry and western blot analysis. In vivo, midjejunal tissue obtained from DON-fed pigs (2.85mg/kg) had a 40% decrease of claudin-4 expression when compared to samples obtained from control-fed pigs (Pinton 2009).

Intestinal barrier disfunction in Crohn’s disease
Changes in the intestinal epithelial barrier function have long been recognized in patients with Crohn’s disease. Intestinal permeability as a marker for barrier integrity can be assessed in vivo by orally administrating test probes and subsequently measuring their concentration in urinary samples. In Crohn’s disease patients, oral administration of probes including the disaccharide lactulose, other macromolecules, or salts (51 chromium-labelled EDTA) result in higher urinary levels of these probes when compared to healthy controls, thus suggesting a decreased barrier function (Sanderson 1987; Teahon 1992). Moreover, the increased intestinal permeability is correlated with the infiltration of both commensal bacteria (Keita 2008). The contribution of barrier disfunction in the pathogenesis of Crohn’s disease is not fully understood. 
That the increased permeability might not only be due to inflammatory lesions characteristic for Crohn’s disease, has been shown in ex vivo segments of the ileum of CD patients. These segments were histologically not inflamed, but showed an increase in endosomal uptake of horse radish peroxidase (HRP), when compared to controls (Soderholm 2004). Endosomal uptake is suggested to be dependent on TNF-alpha, as TNF-alpha mRNA levels are associated with HRP uptake, and TNF-alpha induced HRP uptake in an in vitro T84 cell model (Soderholm 2004). In addition to these changes in transcellular routes, abnormalities in the appearance of tight junctions have been observed. Immunofluorescent labelling of zona occludens 1 (ZO-1) proteins showed interruptions in the tight junction strings specifically in the apical (luminal) epithelium in actively inflamed ileal segments isolated from CD patients, whereas expression was preserved in the underlying endothelium of capillaries (Gassler 2001). Decreases of other tight junctional proteins have been reported in active Crohn’s disease, including claudin-3 (Prasad 2005), claudin-5, -8, and occludin, and these proteins are displaced from the tight junctions into the cytosol (Zeissig 2007). In general, tight junction strand breaks are associated with a decrease in electrical resistance, which was also observed in the epithelial layer of patients with active Crohn’s disease, although resistance was normal in inactive disease (Zeissig 2007).

Tight junction permeability can also be influenced by molecules outside the junctional complex. One of these molecules is myosin light chain kinase (MLCK), which phosphorylates myosin II light chains, and causes condensation of the actomyosin ring. This results in tension on the tight junction, and thereby increasing its permeability (Turner 2000).  Indeed, MLCK expression and activity is upregulated in ileal and colonic segments of patients with inactive and active Crohn’s disease, and this is positively associated with disease severity (Blair 2006). MLCK expression and activation is synergistically regulated by TNF-alpha and IFN-gamma, as shown in Caco-2 cells, and is not dependent on NF-kB activation (Wang 2005). Thus, the decrease in barrier function in CD patients might partly be due to TNF-alpha mediated MLCK expression and activation (Blair 2007). Interestingly, MLCK activation is regulated by ERK1/2, one of the major MAP kinases activated by DON (see below; Klemke 1997).
An increase in single cell apoptosis has also been found in intestinal segments of patients with active Crohn’s disease (Zeissig 2007), and may contribute to the increased permeability as shown in HT29/B6 cells (Bojarski 2000). In line with these findings, the amount of apoptotic cells was decreased in patients treated with anti-TNF-alpha antibodies, and correlated to a higher electrical resistance (i.e. decreased permeability). No changes were observed in tight junction proteins, thus suggesting a direct role (Zeissig 2004). 
Several of the above mentioned studies show the importance of TNF-alpha in various pathways involved in the disruption of barrier function in CD patients. Indeed, treatment with anti-TNF-alpha antibodies reduces the intestinal permeability in CD patients (Suenaert 2002). 

The function of Toll-like receptors in Crohn’s disease and DON stimulation
In order to prevent unwanted inflammatory responses, epithelial cells need to be hyporesponsive to the immunogenic content of the intestinal lumen. In normal tissue, this is conferred by a low expression profile of pattern recognition receptors, such as the toll-like receptors (TLRs). One of the most immunogenic molecular patterns recognized by TLRs is LPS, which is abundantly present in the lumen of the intestinal tract as a major part of the cell wall of gram-negative bacteria. The principle receptor for LPS is TLR4, together with the coreceptors MD2 and CD14, and mediates a proinflammatory response upon recognition. Under normal conditions, epithelial cells of the intestinal tract express low levels of TLR4 and no MD2. Furthermore, the epithelial cell lines T84 and HT-29 are irresponsive to LPS stimulation, as measured by NF-kB activation and IL-8 secretion (Abreu 2003). Transfection of T84 with TLR4 and its coreceptor MD2 restores responsiveness only on the basolateral membrane, which is in an intact barrier not exposed to bacteria of the intestinal lumen (Abreu 2003). However, in an inflammatory setting such as in Crohn’s disease, epithelial cells may become increasingly responsive to LPS. In vitro studies showed that stimulation of the epithelial cell lines T84 and HT-29 with IFN-gamma and TNF-alpha promotes the expression of MD-2 and TLR4 (Abreu 2002; Abreu 2003), and results in IL-8 production upon LPS stimulation (Abreu 2002).  In vivo, TLR4 expression is upregulated on the apical surface of intestinal epithelial cells in both inactive and active Crohn’s disease, as examined by immunohistochemistry (Cario 2000). Others found an increased TLR4 expression only in inflamed areas of the colon (Szebeni 2007). Next to TLR4 expression, epithelial cells in Crohn’s disease patients have increased expression of TLR2 (Szebeni 2007) and TLR8, and are thus likely to be more sensitive to bacterial components. 
Increased recognition of microbial substances in Crohn’s disease might not only occur in epithelial cells, but other cells might also become increasingly exposed due to the ineffective barrier function of epithelial cells. Indeed, in addition to infiltrating bacteria, the TLR2 ligands peptidoglycan-polysaccharide complexes can be found in mucosal and submucosal tissues (Klasen 1994). The potential of these substances to induce inflammatory responses in Crohn’s disease is in line with findings in lamina propria mononuclear cells isolated from Crohn’s disease patients. These cells have a higher activation status marked by TNF-alpha secretion, and this can be further increased upon LPS stimulation (Zareie 2001), thus suggesting increased TLR expression. In addition, dendritic cells isolated from the colon of Crohn’s disease patients have increased amounts of TLR2 and TLR4 (Hart 2005), and mast cells from these patients also have increased amounts of TLR4 (Kabayashi 2007).  
As shown by numerous studies, LPS treatment has the potency to exacerbate the immune response upon DON exposure in vitro and in vivo. Pre-treatment of RAW 264.6 macrophages and murine peritoneal macrophages with LPS elicits a concentration dependent synergistic increase in IL-1beta, IL-6, and TNF-alpha mRNA after DON exposure (250ng/ml). Similar results were obtained for IL-1beta in human monocytes under similar conditions (Pestka 2006).  Stimulation of other TLRs (next to TLR4 by LPS) also results in increased cytokine production upon DON exposure, suggesting that TLR treatment increases the sensitivity to DON in macrophages. (Pestka 2006). The mechanism by which TLR stimulation enhances reactivity to DON is still unknown, but these results imply that DON might also be able to aggravate responses to TLR ligands in macrophages and probably other cells in the intestine of Crohn’s disease patients. 
	In addition to DON, traces of fungal remnants responsible the mycotoxin contamination may also cause contamination, as they are resistant to low temperature baking during the production of some food products (REF). These products may also elicit TLR-mediated immune responses in the intestinal tract. Although the ability to induce TLR-mediated responses for the primary DON-producing fungal contaminants fusarium graminearum and fusarium culmorum is still elusive, other fusarium subspecies have shown to elicit TLR-mediated responses. For example, fusarium oxysporum has been implicated in the upregulation of TLR2, TLR4, and TLR-9 in epithelial cells of the cornea of infected eyes (Jin 2008), and TLR4-deficient mice have a reduced ability to eliminate infection this fungus (Tarabishy 2008). Likewise, remnants of fusarium subspecies in DON-contaminated food may stimulate these TLRs, and the subsequent immune response may be enhanced by concurrent exposure to DON. 

MAP kinases and upstream activation by DON
Mitogen-activated protein (MAP) kinase activation can elicit a wide range of cellular processes, including apoptosis, differentiation and induction of proinflammatory responses (Krishna 2008). The three major families of MAP kinases comprise JNK, ERK, and p38. Various stimuli can trigger activation of these proteins, including inflammatory cytokines, growth factors, environmental stressors such as irradiation, and toxins (Krishna 2008). 
One of the major intracellular responses upon DON exposure is the in vitro and in vivo activation of various MAP kinases. In vitro, DON induces MAP kinase activation in a number of cell lines, including Jurkat cells (10uM), RAW 264.7 macrophages (250ng/ml) (Shifrin 1999; Moon 2002). In vivo, mice orally gavaged with DON (starting from 1mg/kg) induced phosphorylation of the three MAP kinases in spleen cells as early as 15 min after exposure (Zhou 2003a). The ability of DON to induce MAP kinase activation is mediated by binding to ribosomal RNA, the main intracellular target for DON. The resulting cellular stress due to arrest of protein synthesis triggers activation of the MAP kinase pathways, a process called the ribotoxic stress response (Shifrin 1999; Iordanov; Zhou 2003). 
How binding of DON to the major subunit of ribosomes elicits MAP kinase activation is still not completely understood, although recent studies shed light on the molecular events involved. A study by Li and Pestka (2008) showed that DON is able to cleave the 28S rRNA specifically at (at least) two sites in DON stimulated RAW 264.7 cells (1000ng/ml). This is likely to be mediated by intracellular RNases, as no rRNA damage is observed in a cell free system, and RNase expression is upregulated followed DON stimulation of RAW 264.7 cells (125ng/ml). (Li 2008) Bae and Pestka showed that DON exposure of RAW 264.7 macrophages and human U937 monocytes (250 and 500ng/ml, respectively) causes binding of all three major MAP kinases to ribosomal RNA, and subsequently results in their phosphorylation (Bae 2008). 
It is possible that ribosomal RNA scaffolds the binding of both DON and the MAP kinases, resulting in direct activation of the latter. On the other hand, cellular mediators might also be involved, such as Protein Kinase R, an upstream MAP kinase activator which recognizes ds RNA. In RAW 264.7 cells, DON stimulation (250ng/ml) leads to PKR and eIF2alpha phosphorylation, a protein involved in translational arrest, and subsequent degradation of the latter. The involvement of PKR in MAP kinase phosphorylation is evident, as blocking PKR with the inhibitors 2-AP and adenine resulted in inhibition of JNK phosphorylation, and to a lesser extent that of p38 and ERK 1 /2. Inhibiting PKR by an antisense PKR vector in human U-937 cells stimulated with DON had mainly an effect on JNK (Zhou 2003). In light of the ability to recognize ds RNA, it has been speculated that PKR activation is induced by damaged ribosomal RNA, as it binds 28S rRNA and might thus be able to recognize DON induced strand breaks (Gray 2008; Wu 1997). 
Another key player in DON-induced MAP kinase activation is the family of Src tyrosine kinases, as inhibition with PP1 and PP2 effectively ablated DON induced MAP kinase activation in RAW 263.7 cells. One of the members of this family, hematopoietic cell kinase (Hrc), was phosphorylated after DON exposure, and inhibition of its expression reduced DON mediated TNF-alpha levels in cell supernatant (Zhou 2005). Other upstream proteins, including protein kinase A, protein kinase C, and protein phosphatase C are not involved in DON induced MAP kinase phosphorylation, as specific inhibitors have no effect (Zhou 2005). 

MAP kinases and downstream effects by DON 
MAP kinase activation eventually leads to translocation of transcription factors involved in the expression of effectors. Not surprisingly, DON-induced induction of MAP kinases is connected to the activation of transcription factors and subsequent expression of a number of proteins. One of the best defined transcription factors activated by MAP kinases is the group of activating protein-1, which is a heterodimer comprising of jun and fos heterodimes.  In DON fed mice, subunits of the transcription factor activator protein-1 (AP-1), are upregulated and include c-jun, JunB and Fra2 (Kinser 2005). 
A wide range of proteins are expressed under the control of DON-induced activation of MAP kinases, and include COX-2 and cytokines at low concentrations of DON exposure, and proteins mediating apoptosis at high levels of exposure.
COX-2 mRNA and protein levels are dose-dependently upregulated in RAW 264.7 cells after DON exposure (100 to 250 ng/ml). Concomitantly, all three major MAP kinases were phosphorylated, ERK and p38 persistently, and JNK transiently. The upregulation of COX-2 protein levels and activity is dependent on ERK and p38, but not JNK. Furthermore, the former two activate transcription of COX-2, and p38 is also involved in COX-2 mRNA stability upon DON exposure (Moon 2002). 
Cells stimulated with DON at concentrations too low to induce apoptosis, increase the expression of proinflammatory cytokines. For a number of these cytokines, including IL-2, IL-8, and TNF-alpha, DON induced upregulation is mediated by one or more of the major MAP kinases. TNF-alpha expression in DON stimulated RAW 264.7 cells (250ng/ml) is mediated by p38, and to a lesser extent by ERK1/2, as observed in a luciferase reported assay. Costimulation with LPS (1microg/ml) superinduces this effect, suggesting that this pathway exacerbates already existing inflammation. Furthermore, p38 plays a critical role in DON induced mRNA stability of LPS pretreated cells, and protein expression of TNF-alpha, which is also superinduced by LPS. ERK1/2, on the other hand, is only involved in TNF-alpha expression, and JNK has no obvious role in TNF-alpha induction, as shown with inhibitors that are specific for the different MAP kinases (Chung 2003). 
DON (250ng/ml) induces IL-2 expression in Jurkat cells pretreated with PMA and ionomycin, and p38 is the only MAP kinase involved in this response. In the same study, it was shown that all three MAP kinases mediate IL-8 expression in Jurkat cells under similar conditions (Pestka 2005). In human U937 cells, stimulation with DON (500ng/ml) also results in IL-8 mRNA expression, which is dependent on p38 and to a lesser extent JNK and ERK1/2 as shown with there respective inhibitors. Furthermore, IL-6 and IL-1beta mRNA and protein expression induced by DON-exposed PBMCs (500ng/ml) was also dependent on p38 activation. Flow cytometry analysis revealed that CD14+ monocytes were the main PBMCs expressing p38 upon stimulation (Islam 2006).
DON induced apoptosis at high concentrations is also mediated by MAP kinase activation. RAW 264.7 cells exposed to DON (2.5ug/ml) resulted in apoptosis as confirmed by DNA fragmentation, and was mediated by p38 (other MAP kinases were not tested) (Yang 2000). In Jurkat cells, stimulation with high concentrations of DON (500ng/ml) promoted apoptosis, which could partially be inhibited by blocking p38 only (Pestka 2005). Downstream pathways that mediate DON induced apoptosis are also defined. Jurkat T cells stimulated with DON (10uM for 10h or 24h) induce cytochrome c release from mitochondria, Bcl-2 degradation, and a decrease in procaspase-3, all mediators of apoptosis (Nasri 2006). Cytochrome c release is preceded by the formation of a proapoptotic complex that includes the protein Bax. In line with this is the increase in Bax expression in the macrophage cell line J774A.1 after exposure to DON (25uM for 8h to 24h). Furthermore, poly-ADP ribose synthase (PARP), a protein involved in the final steps of apoptosis, is also activated in this cell line upon DON exposure (Marzocco 2009). 

MAPK in Crohn’s disease
The role of MAP kinases in activation of transcription factors that result in proinflammatory gene expression, suggests its involvement in the cytokine disturbance seen in Crohns disease. Indeed, biopsies from Crohn’s disease patients show increased expression of all three major MAP kinases (Waetzig 2002), which was mainly contributed by neutrophils and epithelial cells for p38, and intestinal epithelial lymphocytes and macrophages for JNK (Hommes 2002). The attribution of these pathways in Crohn’s disease inflammation is further shown by selective inhibition of JNK by the pharmacological agent CNI-1493, which induced significant endoscopial healing and decreased TNF-alpha production in CD patients (Hommes 2002). The interaction between TNF-alpha and the MAP kinases seems to be reciprocal, as TNF-alpha also induces phosphorylation of the three MAP kinases in rat colon extracts. Furthermore, ERK, but not the other MAP kinases is involved in TNF-alpha mediated downregulation of epithelial sodium channels (ENaC) (Zeissig 2008). Downregulation of ENaC is one of the major factors in the pathogenesis of Crohn’s disease induced diarrhoea [ref].
The importance of downstream activators in the MAP kinase pathways is underlined by experiments in Mon-Mac-6 cells and THP-1 cells. TNF-alpha production and gene expression in these cells activated with LPS is downregulated after treatment with the probiotic lactobacillus reuteri strain 6475, and this effect is concurrent with a reduce expression of transcription factor activating protein-1 (AP-1) and phosphorylation of its subunit C-Jun (Lin 2008). MAP kinase-interacting serine/threonine kinases (MNKs) are downstream kinases for both p38 and ERK. In LPS-stimulated bone-marrow derived macrophages from SAMP1/YitFc mice, a spontaneous model of Crohn’s disease, inhibition of MNKs results in suppression of TNF-alpha, IL-6 and MCP-1 production (Rowlett 2008). 



